Key Drivers
- Strong liquidity
- Zero revenue
- Large cash burn
AIAI Summary
CLYM has shifted from a discovery-stage optionality play to a milestone-driven, short/medium-term clinical-catalyst investment—with defined mid‑2026 readout windows and a cash runway into 2028 concentrating upside into a narrow set of binary events—so investors should treat it as an event-driven trade rather than a long-term platform bet. Key actionable focus: monitor mid‑2026 efficacy/safety readouts, enrollment cadence, and cash burn (any negative surprises materially raise dilution risk and could trigger sharp downside).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •Large cash burn
CLYM is cash-rich with negligible debt but generates no revenue, large operating losses and negative free cash flow, yet trades at a >2x book premium.
Price Behavior
Key Price Behavior Insights:
- •Breakout confirmed
- •Wide SMA gap
- •Elevated volatility
Over the last month CLYM rallied ~15.8% to a short-term high at $8.41, trading well above the last-month SMA (~$7.01) after a breakout from the mid‑$6s but the sharp move raises profit‑taking risk with supports at $6.11 and $4.65 on failure of momentum.
Sharp run from low‑$4s to $8.41 on 2026-04-10, increasing short-term volatility
Sentiment & News
Key News Insights:
- •FDA Fast Track
- •Webcast May 5
- •CD19 strategic focus
Climb Bio's anti‑CD19 budoprutug won FDA Fast Track for primary membranous nephropathy and the company set an R&D webcast, signaling regulatory momentum and proactive investor engagement.
This updates materially de‑risk the program and should boost investor interest and potential share re‑rating if clinical development continues to progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings